This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG-M1 to IL2 (TTSR). It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2 (TTSR). It contains multiple amino acid substitutions in the antibody —IL-2 junction region of the fusion protein, which eliminate potential T-cell epitopes and results in a less immunogenic protein. The sequence was changed from KSLSLSPGA-APT to KSATATPGA-APT and is denoted as "M1". Also incorporated in this variant is the K to A change at the last amino acid before the junction that has been shown to increase serum half-life of the immunocytokine. This immunocytokine was designed for treating solid tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L013E | anti-EPCAM immunotoxin MOC31 (IgG)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L013D | anti-EPCAM immunotoxin MOC31 (IgG)-DT | Cytotoxicity assay, Functional assay | |
AGTO-L013G | anti-EPCAM immunotoxin MOC31 (IgG)-Gel | Cytotoxicity assay, Functional assay | |
AGTO-L013R | anti-EPCAM immunotoxin MOC31 (IgG)-RTA | Cytotoxicity assay, Functional assay | |
AGTO-L013O | anti-EPCAM immunotoxin MOC31 (IgG)-Bouganin | Cytotoxicity assay, Functional assay |
There are currently no Customer reviews or questions for ACFP-SH074. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.